Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multi-arm study of volrustomig, rilvegostomig, and AZD0901 combinations in gastric or GEJ adenocarcinoma
jRCT2031230074Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of volrustomig, rilvegostomig and sonesitatug vedotin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (9 arms), sponsored by AstraZeneca. Primary endpoints: Objective response rate (ORR) and Progression-free survival (PFS). Started Jul 2023; status: recruiting.
02
Drugs
volrustomigrilvegostomigsonesitatug vedotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031230074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230074.